Reading the tape
NASDAQ: VYNE
VYNE Therapeutics Inc.
Healthcare · Biotechnology
Market Cap
$11.11M
52w High
$1.96
52w Low
$0.28
P/E
-1.08
Volume
1.29K
Outstanding Shares
16.66M
Price vs Fundamentals
Why The Stock Is Moving
Likely multiple compressionModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -53.62%Revenue (TTM): 13.77%FCF (TTM): 2.83%P/S: 90th pct
What changed
The stock fell 53.62% over the last year. Revenue grew 13.77% over the trailing twelve months. Operating margin moved from -8,709.98% to -5,219.12%. Free cash flow grew 2.83% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read changes if operating margin (currently -5,219.12%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Company profile
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions.
CEODavid T. Domzalski
SectorHealthcare
IndustryBiotechnology
Employees13
IPO dateJan 25, 2018
Valuation
Forward P/E—
EV/EBITDA-0.03
Enterprise value$782.72K
Stock splits
Feb 13, 2023↓ Reverse
Every 18 shares became 1
Feb 16, 2021↓ Reverse
Every 4 shares became 1
Profitability & growth
Revenue growth54.76%
Gross margin99.12%▼4.04%vs FY2024
Operating margin-5,219.12%▲40.08%vs FY2024
ROE-95.38%▼24.72%vs FY2024
Analyst consensus
RatingBuy
Target price$5.75▲762.72%
1
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$0.18 · Revenue est $200K
View